Management of stage III non-small cell lung cancer

被引：42

作者：

Tabchi, Samer ^{[1
]}

Kassouf, Elie ^{[1
]}

El Rassy, Elie ^{[2
]}

Kourie, Hampig Raphael ^{[3
]}

Martin, Jocelyne ^{[4
]}

Campeau, Marie-Pierre ^{[5
]}

Tehfe, Mustapha ^{[1
]}

Blais, Normand ^{[1
]}

机构：

[1] Ctr Hosp Univ Montreal, Med Oncol Dept, Montreal, PQ, Canada

[2] St Joseph Univ, Fac Med, Hotel Dieu France, Univ Hosp, Beirut, Lebanon

[3] Univ Libre Bruxelles, Jules Bordet Inst, Oncol Dept, Brussels, Belgium

[4] Ctr Hosp Univ Montreal, Dept Thorac Surg, Montreal, PQ, Canada

[5] Ctr Hosp Univ Montreal, Radiat Oncol Dept, Montreal, PQ, Canada

来源：

SEMINARS IN ONCOLOGY | 2017年 / 44卷 / 03期

关键词：

Non-small cell lung cancer; stage III; chemotherapy; radiotherapy; surgery; combined modality; RANDOMIZED PHASE-III; INDIVIDUAL PATIENT DATA; TRANSBRONCHIAL NEEDLE ASPIRATION; POSTOPERATIVE RADIATION-THERAPY; TRIALIST ASSOCIATION ANITA; INDUCTION CHEMOTHERAPY; CONCURRENT CHEMORADIOTHERAPY; CONSOLIDATION CHEMOTHERAPY; THORACIC RADIOTHERAPY; SEQUENTIAL CHEMORADIOTHERAPY;

D O I：

10.1053/j.seminoncol.2017.10.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Optimal management of patients with locally advanced non-small cell lung cancer remains challenging in the context of this heterogeneous disease. Despite aggressive therapeutic approaches, survival benefits are still unsatisfactory for what might be viewed as a localized malignancy. A combined modality approach offers patients superior outcomes, especially because technological advances and refined surgical procedures now provide better results with fewer complications. Nevertheless, several features of therapy remain controversial and lack formal prospective data. Traditional cytotoxic chemoradiation therapy may have reached a plateau and future perspectives opting to integrate molecularly targeted agents and immunotherapy might be the way to improve outcomes in this disease subset. (C) 2017 Elsevier Inc. All rights reserved.

引用

页码：163 / 177

页数：15

共 80 条

[1] Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04 [J].

Ahn, Jin Seok ;

Ahn, Yong Chan ;

Kim, Joo-Hang ;

Lee, Chang Geol ;

Cho, Eun Kyung ;

Lee, Kyu Chan ;

Chen, Ming ;

Kim, Dong-Wan ;

Kim, Hoon-Kyo ;

Min, Young Joo ;

Kang, Jin-Hyoung ;

Choi, Jin-Hyuck ;

Kim, Sang-We ;

Zhu, Guangying ;

Wu, Yi-Long ;

Kim, Sung Rok ;

Lee, Kyung Hee ;

Song, Hong Suk ;

Choi, Yoon-La ;

Sun, Jong-Mu ;

Jung, Sin-Ho ;

Ahn, Myung-Ju ;

Park, Keunchil .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (24) :2660-U124

[2] Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial [J].

Albain, Kathy S. ;

Swann, R. Suzanne ;

Rusch, Valerie W. ;

Turrisi, Andrew T., III ;

Shepherd, Frances A. ;

Smith, Colum ;

Chen, Yuhchyau ;

Livingston, Robert B. ;

Feins, Richard H. ;

Gandara, David R. ;

Fry, Willard A. ;

Darling, Gail ;

Johnson, David H. ;

Green, Mark R. ;

Miller, Robert C. ;

Ley, Joanne ;

Sause, Willliam T. ;

Cox, James D. .

LANCET, 2009, 374 (9687) :379-386

[3] CONCURRENT CISPLATIN/ETOPOSIDE PLUS CHEST RADIOTHERAPY FOLLOWED BY SURGERY FOR STAGES IIIA(N2) AND IIIB NON-SMALL-CELL LUNG-CANCER - MATURE RESULTS OF SOUTHWEST-ONCOLOGY-GROUP PHASE-II STUDY-8805 [J].

ALBAIN, KS ;

RUSCH, VW ;

CROWLEY, JJ ;

RICE, TW ;

TURRISI, AT ;

WEICK, JK ;

LONCHYNA, VA ;

PRESANT, CA ;

MCKENNA, RJ ;

GANDARA, DR ;

FOSMIRE, H ;

TAYLOR, SA ;

STELZER, KJ ;

BEASLEY, KR ;

LIVINGSTON, RB .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :1880-1892

[4] Survival of patients with resected N2 non-small-cell lung cancer: Evidence for a subclassification and implications [J].

Andre, F ;

Grunenwald, D ;

Pignon, JP ;

Dujon, A ;

Pujol, JL ;

Brichon, PY ;

Brouchet, L ;

Quoix, E ;

Westeel, V ;

Le Chevalier, T .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2981-2989

[5]

Antonia SJ, 2017, NEW ENGLAND J MED

[6] Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301) [J].

Atagi, Shinji ;

Kawahara, Masaaki ;

Yokoyama, Akira ;

Okamoto, Hiroaki ;

Yamamoto, Nobuyuki ;

Ohe, Yuichiro ;

Sawa, Toshiyuki ;

Ishikura, Satoshi ;

Shibata, Taro ;

Fukuda, Haruhiko ;

Saijo, Nagahiro ;

Tamura, Tomohide .

LANCET ONCOLOGY, 2012, 13 (07) :671-678

[7] Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer [J].

Auperin, Anne ;

Le Pechoux, Cecile ;

Rolland, Estelle ;

Curran, Walter J. ;

Furuse, Kiyoyuki ;

Fournel, Pierre ;

Belderbos, Jose ;

Clamon, Gerald ;

Ulutin, Hakki Cuneyt ;

Paulus, Rebecca ;

Yamanaka, Takeharu ;

Bozonnat, Marie-Cecile ;

Uitterhoeve, Apollonia ;

Wang, Xiaofei ;

Stewart, Lesley ;

Arriagada, Rodrigo ;

Burdett, Sarah ;

Pignon, Jean-Pierre .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) :2181-2190

[8] Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: A randomized phase II locally advanced multi-modality protocol [J].

Belani, CP ;

Choy, H ;

Bonomi, P ;

Scott, C ;

Travis, P ;

Haluschak, J ;

Curran, WJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5883-5891

[9] Proton Beam Therapy for Non-Small Cell Lung Cancer: Current Clinical Evidence and Future Directions [J].

Berman, Abigail T. ;

James, Sara St. ;

Rengan, Ramesh .

CANCERS, 2015, 7 (03) :1178-1190

[10] Mediastinal lymph node clearance after docetaxel-cisplatin Neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer:: A multicenter phase II trial [J].

Betticher, DC ;

Schmitz, SFH ;

Tötsch, M ;

Hansen, E ;

Joss, C ;

von Briel, C ;

Schmid, RA ;

Pless, M ;

Habicht, J ;

Roth, AD ;

Spiliopoulos, A ;

Stahel, R ;

Weder, W ;

Stupp, R ;

Egli, F ;

Furrer, M ;

Honegger, H ;

Wernli, M ;

Cerny, T ;

Ris, HB .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (09) :1752-1759

← 1 2 3 4 5 6 7 8 →